%0 Journal Article
%T Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial.
%A de Koning MLY
%A van Dorp P
%A Assa S
%A Pundziute-Do Prado G
%A Voskuil M
%A Anthonio RL
%A Veen D
%A Leiner T
%A Sibeijn-Kuiper AJ
%A van Goor H
%A van Veldhuisen DJ
%A van der Meer P
%A Nijveldt R
%A Lipšic E
%A van der Harst P
%J JACC Basic Transl Sci
%V 8
%N 10
%D 2023 Oct
%M 38094689
%F 9.531
%R 10.1016/j.jacbts.2023.06.001
%X In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.